Work

In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.

Year: 2019
Type: dissertation
Abstract: Hepatitis C Virus (HCV) is an escalating global healthcare and economic burden that requires extensive \nintervention to alleviate its control. Over the years, drug design efforts have produced many anti-HCV \ndrugs; however, due to drug resistance brought on by numerous genetic variations of the virus and lack \nof specificity and stability, current drugs are rendered ineffective. The situation has been further \nintensified by the absence of a viable vaccine. For these reasons, continuous HCV research is imperative \nfor the design and development of promising inhibitors that address the challenges faced by present \nantiviral therapies. Moreover, exposure of previously neglected viral protein targets can offer another \npotentially valuable therapeutic route in drug design research. \nStructure-based drug design approaches accentuate the development of small inhibitor molecules that \ninteract with therapeutic targets through non-covalent interactions. The unexpected discovery of \ncovalent inhibitors and their distinctive nature of instigating complete and irreversible inhibition of \ntargets have shifted attention away from the use of non-covalent drugs in antiviral treatment. This has \nled to significant progress in understanding covalent inhibition regarding their underlying mechanism \nof action and in the design of novel covalent inhibitors that work against biological targets. However, \ndue to difficulties arising in its application and resultant safety, the pharmaceutical industry were \nreluctant to pursue this strategy. With the use of rational drug design, a novel strategy was then proposed \nknown as selective covalent inhibition. Due to the lack of competent protocols and information, little is \nknown regarding selective covalent inhibition \nThis study investigates three biological HCV targets, NS3 protease, RNA helicase and NS5B RNAdependent RNA polymerase. With constantly evolving viruses like HCV, computational methods \nincluding molecular modelling and docking, virtual screening and molecular dynamic simulations have \nallowed chemists to screen millions of compounds to filter out potential lead drugs. These in silico \napproaches have allowed Computer-Aided Drug Design as a cost-effective strategy to accelerate the \nprocess of drug discovery. \nThe above techniques, with numerous other computational tools were employed in this study to fill the \ngap in HCV drug research by providing insights into the structural and dynamic changes that describe \nthe mechanism of selective covalent inhibition and pharmacophoric features that lead to unearthing of \npotential small inhibitor molecules against Hepatitis C. \nv \nThe first study (Chapter 4) provides a comprehensive review on HCV NS3/4A protein, current therapies \nand covalent inhibition as well as introduces a technical guideline that provides a systematic approach \nfor the design and development of potent, selective HCV inhibitors. \nThe second study (Chapter 5) provides a comprehensive understanding concerning the implications of \nselective covalent inhibition on the activity of HCV NS5B RNA-dependent RNA polymerase, with \nrespect to key components required for viral replication, when bound to a target-specific small inhibitor \nmolecule. \nThe third study (Chapter 6) is preliminary investigation that uses Pharmacophore-based virtual \nscreening as an efficient tool for the discovery of improved potential HCV NS3 helicase inhibitors. The \npharmacophoric features were created based on the highly contributing amino acid residues that bind \nwith highest affinity to the weak inhibitor, quercetin. These residues were identified based on free \nenergy footprints obtained from molecular dynamic and thermodynamic calculations. Post molecular \ndynamic analysis and appropriate drug-likeness properties of the three top-hit compounds revealed that \nZINC02495613 could be a more effective potential HCV helicase inhibitor; however, further validation \nsteps are still required. \nThis study offers a comprehensive in silico perspective to fill the gap in rational drug design research \nagainst HCV, thus providing an insight into the mechanism of selective covalent inhibition, uncovering \na previously neglected viral target and identifying possible antiviral drugs. To this end, the work \npresented in this report is considered a fundamental platform to advance research toward the design and \ndevelopment of novel and selective anti-HCV drugs.
Language: English
Subfield: Drug Discovery
Open Access status: green
OpenAlex ID: W2996614957
Cites: 309
Cited by: 2
Related to: 10